Healthcare Providers
Healthcare Providers

How You Can Help

There are options available for your patients with EGFR-Positive Non-Small-Cell Lung Cancer (NSCLC)

Advances in Treatment

Tremendous advances have been made in the treatment of NSCLC that is positive for epidermal growth factor receptor (EGFR) mutations.1From 2003-2016, nearly half of the new medications approved for the treatment of lung cancer addressed this particular molecular profile.1

Despite this progress, there is still a need for investigational medicines that aim to target EGFR mutations, as some lung cancers with EGFR mutations don’t respond to current targeted medications, and those that do almost always become resistant over time.

Investigational medicines are currently
being studied for adults with NSCLC.

The following research studies are currently evaluating the safety and efficacy
of investigational medicines for the treatment of NSCLC in patients with EGFR.

The CHRYSALIS Study is enrolling adults with advanced or metastatic NSCLC with a primary MET Exon 14 skipping mutation. It is also enrolling adults with adenocarcinoma or squamous cell carcinoma histology who have wild-type EGFR/wild-type ALK with demonstrated expression of EGFR protein, MET protein, or both proteins (via centralized immunohistochemistry).
Download the HCP CHRYSALIS Study Guide.
The CHRYSALIS 2 Study for adults with advanced or metastatic NSCLC with uncommon non-Exon 20 insertion activating mutations.
Download the HCP CHRYSALIS 2 Study Guide.
The MARIPOSA Study for adults with newly diagnosed locally advanced or metastatic NSCLC with EGFR Exon 19 deletion or Exon 21 L858R substitution.
Download the HCP MARIPOSA Study Guide.
The MARIPOSA 2 Study for adults with locally advanced or metastatic NSCLC with EGFR Exon 19 deletion or Exon 21 L858R substitution.
Download the HCP MARIPOSA 2 Study Guide.
The PAPILLON Study for adults with advanced or metastatic NSCLC that has EGFR Exon 20
insertion mutations.
Download the HCP PAPILLON Study Guide.
Next Generation Sequencing (NGS) over Standard Biomarker Testing

NGS is a DNA sequencing technology method that can detect abnormalities across the entire genome, including substitutions, deletions, and insertions. Using NGS, multiple genes can be tested for mutations simultaneously, often in less time and with less cost than standard sequencing approaches.2

The more we learn, the farther we can go.

If you have a EGFR-positive patient that may be a candidate for one of these clinical research studies, or would like to share this information with a colleague, you can do any of the following:

Share & Educate

Share this website to provide education and awareness about these investigational research studies. Patients can also take a simple questionnaire to see if they may be eligible.

Share This
Encourage Contact

Encourage your patient to contact our nurses to ask any questions they may have and see if they may be eligible to participate in a study.

Call 1-855-218-4395
Download & Share

Download and share a patient brochure or fact sheet with more information on the Chrysalis, Chrysalis 2, Mariposa 2 or Papillon Study.

Healthcare Providers

Learn more about these clinical research studies.

Visit Global Trial Finder to locate Janssen clinical research studies that may be looking for participants all around the world.

Additional Resources for Healthcare Providers
  • The Association of Community Cancer Centers (ACCC)
    A non-profit committed to education and advocacy support in adapting and responding to changes and challenges in the delivery of quality cancer care.
  • International Associate for the Study of Lung Cancer (IASLC)
    A foundation dedicated to the eradication of all forms of lung cancer. The IASLC's membership consists of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers.
If you have EGFR-Positive Non-Small-Cell Lung Cancer, your journey may include a different path. 

The more we learn, the farther we can go.